绝经后女性身高丢失是否可用于骨折风险评估:GO研究结果
该研究纳入1735名55岁以上绝经后女性,测量当前身高与成年早期最大身高计算身高丢失(HL),并采用FRAX、Garvan和POL-RISK计算骨折风险。结果显示平均HL为3.95±3.24 cm,HL与各骨折风险评估工具计算的风险显著相关(r=0.13–0.39,p<0.0001);HL达3–4 cm或以上可视为骨折风险增加的简单指标。
要点
- 绝经后女性平均身高丢失为3.95±3.24 cm,与骨折风险评估工具结果显著相关。
- 身高丢失3–4 cm或以上可作为骨折风险增加的简单临床指标。
- FRAX主要骨折20%阈值对应身高丢失约6.5 cm。
核心结论
- 身高丢失3–4 cm或以上可视为绝经后女性骨折风险增加的简单指标,其信息与基于多变量方法的在线骨折风险评估工具结果相似。
研究设计与样本
- GO研究纳入1735名55岁以上绝经后女性,平均年龄68.15±8.16岁,在骨质疏松门诊招募。
- 采用FRAX计算10年主要和髋部骨折概率,Garvan计算5年和10年任何及髋部骨折风险,POL-RISK计算5年任何骨折风险。
- 股骨颈骨密度用Prodigy设备(Lunar,GE,美国)测定,身高用壁式身高计测量并与受试者自报成年早期最大身高比较。
主要发现
- 199名女性当前身高与成年早期相比无变化,其余1536名身高下降。
- 全组平均身高丢失为3.95±3.24 cm,与各工具计算的骨折风险显著相关(r范围0.13–0.39,p<0.0001)。
- 在骨折风险接近推荐治疗阈值的患者中,身高丢失约为3–4 cm,但FRAX主要骨折常用阈值20%对应身高丢失约6.5 cm。
- 身高丢失3.5–4 cm的208名受试者中,FRAX主要骨折值为6.83±3.74。
关键数值与推荐
- 身高丢失3–4 cm或以上可考虑为骨折风险增加的简单指标。
- FRAX主要骨折20%治疗阈值对应身高丢失约6.5 cm。
- 身高丢失3.5–4 cm者FRAX主要骨折值为6.83±3.74。
临床怎么用
- 临床可测量绝经后女性当前身高并与成年早期最大身高比较,计算身高丢失。
- 身高丢失达3–4 cm或以上时应考虑进一步骨折风险评估。
- 身高丢失信息可与FRAX、Garvan或POL-RISK等工具结果结合用于风险判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Human body height loss of 3-4 cm or more may be considered a simple indicator of increasing fracture risk, where the information is very similar to the results from fracture risk assessments by available online calculators, all of them based on a multiple variable approaches. INTRODUCTION: The aim of the study was to assess the relationship between body height loss (HL) and fracture risk in postmenopausal women from the Gliwice Osteoporosis (GO) Study. METHODS: The study sample included 1735 postmenopausal women, aged over 55 years and recruited at the Osteoporotic Outpatient Clinic. The mean age of the study participants was 68.15 ± 8.16 years. Fracture risk was established, using the fracture risk assessment tool (FRAX) (10-year probability of major and hip fractures), the Garvan calculator (any and hip fractures, 5 and 10 years) and the Polish (POL-RISK) algorithm, available at www. fracture - risk .pl (any fractures, 5 years). Bone densitometry at the femoral neck was performed, using a Prodigy device (Lunar, GE, USA). Body heights were measured before bone densitometry, using a wall stadiometer and compared with the maximum body heights, measured in early adulthood and reported by the study participants themselves. RESULTS: In 199 women, the body heights, measured during the study, did not change in comparison to their corresponding values in early adulthood, while being decreased in the other 1536 women. The mean height loss (HL) in the whole study group was 3.95 ± 3.24 cm. That HL correlated significantly with the calculated fracture risk (the r range from 0.13 to 0.39, p < 0.0001). In general, regarding the patients with fracture risk close to the recommended therapeutic thresholds, HL was around 3-4 cm, except of the values from the FRAX calculator for major fractures, where the commonly used therapeutic threshold (20%) was related to HL of approximately 6.5 cm. In subjects with HL between 3.5 and 4 cm (n = 208), the FRAX value for major fractures was 6.83 ± 3.74. CONCLUSIONS: Body height measurements, carried out to establish HL, provide an important information for clinical practice, where HL of 3-4 cm or more may be considered a simple indicator of increasing fracture risk.
引用
- Pluskiewicz W, Adamczyk P, Drozdzowska B, et al. Height loss in postmenopausal women-do we need more for fracture risk assessment? Results from the GO Study. Osteoporos Int. 2021. PMID: 33818635. doi:10.1007/s00198-021-05941-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。